We are thrilled to have more than 2000 patients registered on Add-Aspirin in the New Year, which reflects the hard work and dedication of site staff over the festive season. 1000 participants have now been registered in the breast cohort, and more than 1400 participants have been randomised overall.
We would like to wish you a very happy new year, and look forward to continuing to work with you in 2017!
Christmas & New Year Opening Times
Please note the Randomisation phoneline will be closed from 5pm on 23rd December until 2nd Jan and will reopen at 9am on 3rd January 2017.
There will be limited MRC CTU cover between 28th - 30th December and urgent queries will be prioritised.
The last date for sending translational samples to biobanks will be 21st December 2016.
Wales Cancer Bank will re-open on January 3rd and Tayside Tissue Bank will re-open on January 4th 2017. Any samples taken on 2nd January should be refrigerated until the 3rd when they can be posted to the relevant biobank.
Add-Aspirin 1 Year Anniversary - 1000 patients randomised!
October 2016 marks one year since the Add-Aspirin trial opened to recruitment across the UK. Since then 150 hospitals have chosen to participate with the 1000th patient randomised as of 12th October 2016, making it the largest randomised controlled trial to examine the relationship between cancer and aspirin.
Congratulations to to all sites who have contributed to the success of Add-Aspirin across the last year.
August Newsletter - 1000th Patient Registered!
On July 15th the 1000th patient was registered to Add-Aspirin. We would like to thank all sites across the UK for your hard work in reaching this milestone in the trial.
For more information please see the August Newsletter in the members area.
Self Evident Corrections (SECs)
The Self-evident corrections, or SECs, are specific situations where data given on CRFs will be corrected by the trial team when entered on the database. These are very useful for sites as it means you, the site, will not be notified of these queries, nor will sites need to confirm these corrections.
- For GCP compliance, the SECs need to be acknowledged and signed off by the overall PI at your site as well as the first point of contact. Once complete, the faxback should be sent to +44 (0)20 7670-4818. Please return the completed faxback document to the Add Aspirin trial team as soon as possible.
MRC CTU at UCL Joint Urological Trials regional meetings 2016
The MRC CTU at UCL will be hosting four regional Urological Trials meetings to highlight various aspects of urological trials within the Unit, during which there will be a talk from the Add-Aspirin Chief Investigator, Professor Ruth Langley. These meetings are aimed at investigators and research teams at sites. There will be time for discussion and questions, and an opportunity to meet some of the Add-Aspirin team.
We are pleased to announce that booking is now open for the London and Liverpool meetings.
Meetings will be held at:
London - Thursday 16th June (10:00 - 15:10) Henry Wellcome Auditorium
Register here Wellcome Collection
View the agenda 183 Euston Road
Liverpool - Thursday 30th June (13:00-16:15) BAUS 2016 Annual Scientific Meeting
Register here BT Convention Centre
View the agenda Kings Dock
Please note that this meeting is also open to people not registered for the BAUS conference.
Bristol - Thursday 7th July Holiday Inn
Register here Bond Street
View the agenda Bristol
Glasgow - Monday 12th September Main Senate Room
Register here University of Glasgow
View the agenda University Avenue
International Clinical Trials Day - Friday 20th May 2016
International Clinical Trials Day took place on 20th May this year. To mark the event, UCL's Institute of Clinical Trials and Methodology held a special half-day event entitled Key Advances in Clinical Trials. This event showcased some of the recent ground-breaking trials activity conducted at the four clinical trials units at UCL. Slides from the event and further information can be found here.
The Add-Aspirin team would like to thank all those taking part in clinical trials.
“Daily aspirin recommended in US but still not in Britain”
This headline recently appeared in the Telegraph. The article discusses new recommendations about aspirin use from a group of health officials in the United States (US), and how they differ to those in the United Kingdom (UK). The US recommendations suggest that people aged between 50 and 69 who are known to have a moderate increased risk of heart disease should consider taking daily aspirin to reduce the risk of developing bowel cancer as well as heart and circulatory problems.
This is not the current recommendation in the UK, and doesn’t provide a recommendation for those who have had cancer. The best way to find out more about the health benefits of aspirin is in a clinical trial.
The Add-Aspirin trial is testing whether daily aspirin can prevent cancer returning after cancer treatment, and will also test the other potential health benefits of aspirin including the prevention of heart and circulatory problems. It will also assess whether aspirin help prevent new cancers developing. The results of trials such as Add-Aspirin will help guide health officials on future recommendations about aspirin use.
World Cancer Day 2016
To mark World Cancer Day, Cancer Research UK are taking a look at how research that is happening in partnership with other countries is making the future brighter for cancer patients across the globe.
The Add-Aspirin trial, running in the UK, and soon to be India, is looking at whether aspirin can prevent cancer from coming back.
"Every day we see patients who are unable to afford the costs of expensive cancer therapy - they would benefit greatly from in inexpensive form of cancer treatment like aspirin," says Dr Conjeevaram Pramesh, from the Tata Memorial Hospital, Mumbai, leading the Add-Aspirin trial in India. "There is immense potential for a simple, cost-effective treatment like aspirin to help people with Cancer in India and other resource-poor countries."
But importantly, people should not start taking aspirin without first speaking to their doctor, as aspirin isn't suitable for everyone and it can have serious side effects. Please speak to your oncologist or research nurse if you would like to join the Add-Aspirin trial.
Read more here.
Guardian: Aspirin 'may double life expectancy of cancer patients'
This headline recently appeared in the Guardian with a number of other newspapers reporting on the same story. The report was about a large study conducted by researchers in the Netherlands. The researchers used national databases to identify people who had been diagnosed with cancer in the digestive system and see whether or not they took aspirin following their diagnosis. They followed this group of nearly 14,000 people over a number of years to see how long they lived after their cancer diagnosis. The results were presented at the European Cancer Congress 2015.
In keeping with other previous studies of this kind, the researchers found that those people who took aspirin were more likely to live longer than those who did not, and that this was particularly notable for people with cancer in the oesophagus (food pipe), colon (large bowel) or rectum. There are some important limitations to this type of study – in particular, there will be many other factors that affect how long a person lives following a cancer diagnosis, and these may differ between those people who did and did not take aspirin. Also, since the information was collected in national databases a number of years ago, it may not be possible to go back and check the details.
The best way to confirm the findings from this and other similar studies is to do a clinical trial. This is the aim of the Add-Aspirin trial. Some participants will take aspirin and others will take a placebo (dummy) tablet – this will be decided at random in order to make a fair comparison. They will be followed up for a number of years to collect all of the relevant information to see whether aspirin can delay or prevent their cancer from returning. This new study further highlights the need for a trial to answer this question once and for all.
BBC News: Aspirin 'might boost cancer therapy'
This headline recently appeared on the BBC news, with a number of other newspapers reporting on the same story. The report was about a study in mice by researchers at the Francis Crick Institute. The scientists looked at drugs known as Cox-inhibitors (aspirin is a type of Cox-inhibitor). Their results suggested that using these drugs alongside cancer treatments that are designed to allow the body’s own immune system to attack the cancer may make the treatment more effective. Since this was a study in mice, further research will be needed before it is known whether or not this will be a useful approach in treating people with cancer and which people it might help. The study was published in the journal Cell.
In the Add-Aspirin trial, participants will take aspirin (or a placebo) after initial treatment for cancer for a period of at least 5 years. Aspirin may work in different ways. In the trial, we are mainly trying to find out if aspirin can stop cancers spreading or coming back after initial treatment. The cancer treatments that participants will have received before joining the trial are not the same as those studied in this recent report (as these treatments are not currently used for the types of cancer being studied in the Add-Aspirin trial). We do not believe that this new information affects the rationale for the trial, but it may help us to better understand how aspirin may work against cancer.
The Times: Daily aspirin found to reduce bowel cancer risk
This headline recently appeared in The Times. It was a report of a large Danish study which has been published in the Annals of Internal Medicine. The researchers looked at cancer registries and data on aspirin prescriptions for more than 10,000 individuals in Denmark. They aimed to see whether taking aspirin affected an individual’s risk of developing bowel cancer. They also looked at use of other non-steroidal anti-inflammatory drugs (NSAIDs), for example, ibuprofen.
In keeping with many previous studies, the researchers found that people who took aspirin were less likely to be diagnosed with bowel cancer although, importantly, this only applied to individuals who took aspirin regularly over a long period of time (5 years or more). There are a number of limitations to this type of study – for example, information on other risk factors for developing bowel cancer were not available and may have affected the results. But the results are consistent with previous studies showing that long-term aspirin use appears to reduce the risk of bowel cancer. Participants in the Add-Aspirin trial will have had a previous diagnosis and treatment for cancer, and so their risk of cancer returning will be higher than in the general population and they may derive an even greater benefit from taking aspirin. Participants in the Add-Aspirin trial will be asked to take aspirin (or a placebo) for a period of at least 5 years, so that the effects of long-term use can be seen. We do not believe that this new information affects the rationale for the trial but we will continue to monitor all new information carefully.